IRAC Case Briefs and Analyses
IRAC Briefs Regulatory risks are risks that many domestic and international organizations assume when it fails to comply with the government regulation. Whether federal, state, or international non-compliance puts an organization at risk of negative publicity, diminished revenue, tort liability and the total demise of the organization existences within the market completely. The combination of domestic and international business presents more regulatory risk with opportunities for expansion, growth and income than domestic business alone. Given the cases provided, this paper will focus on ways to identify applicable regulatory compliance requirements for business situations in addition to evaluating legal risks associated with domestic and international business activity.
IRAC Case Brief #1: Tewelde’s Lafitte Drugs v. Louisiana Board of Pharmacy
FACTS:
Licensed in 1977, Taddese Tewelde owns and serves as a pharmacist since 1981at Tewelde's Lafitte Drugs (Lafitte Drugs) in Lafitte, Louisiana. In 2010, Lafitte Drugs ordered a significantly larger amount of schedule II drugs from Morris & Dickson Drug Company. Because of this substantial increase in sales of schedule II narcotics and learning that most of the prescriptions were from Texas health care providers, Morris and Dickson, as it was required to do, reported the purchases to the United States Department of Justice Drug Enforcement Administration (DEA) and ceased all sales of controlled dangerous substances to the pharmacy (NO. 2011 CA 2244, 2012).
ISSUES:
1. Did Twelde Drugs violate the provision of the provisions of the Louisiana Pharmacy Practice Act] and any compliance regulations?
2. Did Taddese Tewelde execute his fiduciary duties to verify the prescription by calling the office of the health care provider that issued the prescription?
RULE:
On August 24, 2011, LAC 46: Liii. 2747 B.4 was adopted by Louisiana Board of Pharmacy to remind Pharmacists if their corresponding responsibilities
IRAC Case Brief #1: Tewelde’s Lafitte Drugs v. Louisiana Board of Pharmacy
FACTS:
Licensed in 1977, Taddese Tewelde owns and serves as a pharmacist since 1981at Tewelde's Lafitte Drugs (Lafitte Drugs) in Lafitte, Louisiana. In 2010, Lafitte Drugs ordered a significantly larger amount of schedule II drugs from Morris & Dickson Drug Company. Because of this substantial increase in sales of schedule II narcotics and learning that most of the prescriptions were from Texas health care providers, Morris and Dickson, as it was required to do, reported the purchases to the United States Department of Justice Drug Enforcement Administration (DEA) and ceased all sales of controlled dangerous substances to the pharmacy (NO. 2011 CA 2244, 2012).
ISSUES:
1. Did Twelde Drugs violate the provision of the provisions of the Louisiana Pharmacy Practice Act] and any compliance regulations?
2. Did Taddese Tewelde execute his fiduciary duties to verify the prescription by calling the office of the health care provider that issued the prescription?
RULE:
On August 24, 2011, LAC 46: Liii. 2747 B.4 was adopted by Louisiana Board of Pharmacy to remind Pharmacists if their corresponding responsibilities